Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared…
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for maj…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated gl…
LIFE COURIERS, a global healthcare and life-science logistics services provider (www.lifecouriers.com), is pleased to a…
Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik A…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement f…
The Executive Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) resolved at its meeting today, with the approval of…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agre…
Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreem…
By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston…